Emyria (ASX:EMD) has announced leadership changes designed to position it to meet anticipated growth in demand for its unique care programs and new forms of therapy.

Latest Video
New Stories
-
Montu pushes for national standards at Productivity Commission inquiry
June 17, 2025 - - Latest News -
Canadian appointed to lead New Zealand's Pharmac
June 17, 2025 - - Latest News -
US FDA approves CSL's treatment for hereditary angioedema
June 17, 2025 - - Latest News -
Australia's system is more uniform than the US, but not uniformly better
June 17, 2025 - - Latest News -
Australian company secures FDA approval to progress development of CAR-T therapy
June 16, 2025 - - Latest News -
These systems are and always have been more similar than most realise
June 16, 2025 - - Latest News -
Confirmation the UK has agreed to review medicine prices in response to US demand
June 16, 2025 - - Latest News